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Introduction Symptoms of ovarian cancer are often vague and
consequently a high proportion of women with ovarian cancer
are not referred to the appropriate clinic.
Objective To identify diagnostic factors for ovarian cancer.
Design A qualitative and quantitative study.
Setting Four UK hospitals.
Sample One hundred and twenty-four women referred to hospital
with suspected ovarian malignancy.
Methods Women were interviewed prior to diagnosis (n = 63),
or soon after. A thematic analysis was conducted. Emergent
symptoms were quantitatively analysed to identify distinguishing
features of ovarian cancer.
Main outcomes Symptoms in women with and without ovarian
cancer.
Results Diagnoses comprised 44 malignancies, 59 benign
gynaecological pathologies and 21 normal ﬁndings. Of the
malignancies, 25 women had stage III or more disease, with an
average age of 59 years. The benign/normal cohort was signiﬁcantly
younger (48 years). Multivariate analysis revealed persistent
abdominal distension (OR 5.2, 95% CI 1.3–20.5), postmenopausal
bleeding (OR 9.2, 95% CI 1.1–76.1), appetite loss (OR 3.2, 95% CI
1.1–9.2), early satiety (OR 5.0, 95% CI 1.6–15.7) and progressive
symptoms (OR 3.6, 95% CI 1.3–9.8) as independent, statistically
significant variables associated with ovarian cancer. Fluctuating
distension was not associated with ovarian cancer (OR 0.4, 95% CI
0–4.1). Women frequently used the term bloating, but this
represented two distinct events: persistent abdominal distension and
fluctuating distension/discomfort.
Conclusions Ovarian cancer is not a silent killer. Clinicians
should distinguish between persistent and ﬂuctuating distension.
Recognition of the signiﬁcance of symptoms described by women
could lead to earlier and more appropriate referral.
Keywords Diagnosis, mixed methods, ovarian cancer, referral,
symptoms.
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Introduction
Ovarian cancer is the most common gynaecological cancer in
UK women.1 Each year, around 7000 women in the UK are
diagnosed with ovarian cancer, and approximately 4400
women die from it.2 One of the most important prognostic
factors is the stage at diagnosis. Women with early-stage dis-
ease have 5-year survival rates in excess of 70%, whereas that
for advanced disease is around 15%.2 The majority of women
are diagnosed at a late stage, and therefore, overall 5-year
survival rates are correspondingly low at 30–40%.2
The presenting symptoms of ovarian cancer are not speciﬁc
and are often accepted by women as normal changes associ-
ated with ageing, menopause and previous pregnancies.3 As
a result, ovarian cancer is often referred to as the ‘silent killer’,
and it is commonly believed that no symptoms are evident in
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quently difﬁcult due to the fact that the presenting symptoms
for ovarian cancer are similar to those for gastrointestinal
disease.4 Women often follow convoluted referral pathways
before being correctly diagnosed, with 50% of women not
being referred directly to gynaecological cancer clinics. This
is due to both women and GPs failing to recognise the pre-
senting symptoms of ovarian cancer.5,6
Given the relationship between stage at diagnosis and sur-
vival, there is an increasing emphasis on the need to develop
effectivestrategiesforearlierdiagnosis,includingtheidentiﬁca-
tionofsymptomspredictiveofovariancancer.Severalprevious
researchstudieshavecomparedsymptomsamong womenwith
ovarian cancer and those without.7–10 However, the methods
used to identify potential symptoms have been limited as they
have frequently relied on medical records,8,9 which can under-
estimate the number and severity of symptoms. Other studies
have collected data retrospectively directly from women.6,11
However,asthe5-year prognosis ofovarian cancerispoor, this
may introduce survivor bias. Additionally, in several cases,
symptom data have been recorded using checklists, which have
been limited in the range of symptoms.6,10–17
This paper reports the results of a study that used both
qualitative and quantitative methods to investigate symptoms
associated with ovarian cancer.
Methods
Women urgently referred with a suspicion of ovarian cancer
or recently diagnosed withovarian cancer wererecruited from
hospital clinics. In order to reduce recall and survivor biases,
participants were interviewed prior to diagnosis. However,
this was not possible in all cases (e.g. women who had been
undergoing investigations in other hospital departments);
therefore, some women were interviewed shortly after a diag-
nosis was made. The method of diagnosis (radiological imag-
ing or histopathology) was independent of the study and did
not inﬂuence the timing of the interview.
Potential participants were provided with a study informa-
tionpackageonarrivalatthehospitalfollowingtheGPreferral.
Researchers contacted those who returned an initial consent
form to arrange a convenient time for the interview. Due to
the pragmatic way in which recruitment packs were distributed
towomen,completedataonnonrespondersarenotavailable.A
ﬁnal consent form was completed at the interview. No women
withdrew from the study at the time of the interview.
Final diagnoses were obtained from hospital records.
Semistructured interviews were tape recorded and tran-
scribed verbatim. A thematic analysis of the interview data
was conducted. This involved obtaining a detailed knowledge
of the content of the interview transcripts through in-depth
reading and consideration of the text. A thematic framework
was developed by identifying key issues within the data (using
a priori issues and questions from the aims of the study in
addition to issues raised by the participants). Passages of text
were coded according to each issue or theme identiﬁed, and
the data were subsequently arranged by each issue or theme.18
The qualitative software package ATLAS-ti (Scientiﬁc Soft-
ware Development, Berlin, Germany)19 was used. Symptom
experiences for women diagnosed with and without ovarian
cancer were compared.
Formal sample size calculations for the quantitative analy-
sis were not performed at the outset of the study because
a ﬁnal decision on the number of variables to be included
in the regression model could not be made a priori. However,
Altman suggests that the number of variables to be considered
should be restricted to one-tenth of the sample size, and the
maximum size of a model to be the square root of the sample
size.20 By this rule, including data for 120 women in the pre-
liminary analysis would allow 12 variables to enter the model,
with 10 or 11 explanatory variables in the ﬁnal model.
Following the thematic analysis, the data from the inter-
views with women were transformed from qualitative data
into quantitative data. An assessment was made of the symp-
toms experienced by each individual (present or absent status
was recorded for each symptom, which emerged from the
qualitative analysis). This coding was based on the descrip-
tions of the symptoms that women used.
Data were treated as that from a prospective cohort study
of symptoms (with follow up continuing until a diagnosis was
obtained). The symptom proﬁles were analysed to identify
likely discriminatory features indicative of ovarian cancer
using SPSS (SPSS Inc., Chicago, IL, USA)21 and Stata (Stata-
Corp LP, College Station, TX, USA).22
First, univariate associations were explored between each of
the symptom variables and the dependent outcome of ovarian
cancer. Statistical signiﬁcance was assessed using the chi-
squared test or Fisher’s exact test. The Mann–Whitney U test
was used to explore the distribution of age with outcome
group. Symptoms that reached a signiﬁcance level of 0.05
(and had greater than ﬁve expected numbers) were consid-
ered for multivariate analysis using forward stepwise regres-
sion. Other potential confounding symptoms such as vaginal
bleeding were also included in the model. The signiﬁcance
level for entry into the model was P = 0.05 and for the criteria
for removal from the model was P = 0.1.
Crude and adjusted odds ratios were calculated for the
variables that remained in the ﬁnal multivariate model.
The London MREC granted ethical approval (MREC/
02/2/95).
Results
Interviews were conducted with 124 women. Final diagnoses
comprised 44 malignancies, 59 benign gynaecological
pathologies and 21 normal ﬁndings. Of the 44 malignancies,
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were gynaecological cancers, primary site unknown. The four
women diagnosed with peritoneal and genital organ (not oth-
erwise speciﬁed) cancers were included with the ovarian cancer
cases as the occurrence of such tumours can be clinically and
histologically indistinguishable from ovarian cancer.23 Twenty-
ﬁve women had stage III or more advanced disease. The aver-
age age of the group of women with cancer was 59 years, with
the benign/normal cohort having a signiﬁcantly younger age of
48. Demographic details are provided in Table 1.
Approximately 60% of the women with cancer were inter-
viewed before diagnosis (26/44), and 46% (37/80) of the non-
cancer group were interviewed prior to diagnosis.
Qualitative results
All women diagnosed with ovarian cancer experienced symp-
toms before diagnosis demonstrating that ovarian cancer is
not a silent killer. However, these events were not interpreted
as warning signs or symptoms—women saw them as normal
changes attributable to ageing, weight gain or other natural
physiological processes. This lack of recognition contributed
to a delay in seeking medical attention; the median dura-
tion of symptoms before interview or diagnosis (whichever
occurred first) was 12 months. The symptoms encountered
included abdominal pain, distension, postmenopausal bleed-
ing (PMB), fatigue, nausea, vomiting, altered bowel and uri-
nary function, loss of appetite and others.24
The terminology used by women to name their symptoms
did not always accurately describe the symptoms they ex-
perienced. The case of persistent abdominal distension and
ﬂuctuating distension/discomfort (both of which women fre-
quently called ‘bloating’) is a striking example. Initially, the
women seemed to indicate that they were experiencing a tem-
porary, ﬂuctuating sensation of enlargement or discomfort.
When questioned in detail about how they were affected by
this symptom, it became apparent that many were experienc-
ing persistent abdominal distension. As a result, during the
analysis of the interview transcripts, the coding of bloating
and distension was based on women’s experiences of these
symptoms and not on the terminology used to describe them.
The following passage illustrates how the term ‘bloat’ was
used by a woman to describe persistent change (this was
coded as distension by the researchers).
Ov 29, 60-69
I’m a size 14 and I went and bought a size 20 skirt last week
and it’s not big enough. I put it on but I could only stand it for
half an hour, even my knickers are leaving a big red line all
round me. It is so, you’ve no idea how uncomfortable it its,
it’s just so up, you feel like you want to stick a pin in it and let
loads of air out you know—really bloaty
It is worth noting that distension could occur with or with-
out concomitant bloating.
Table 1. Demographic details of the 124 eligible women
Women with
cancer
(n 5 44)
Women
without
cancer (n 5 80)
Age (years)
,20 2 0
20–29 2 4
30–39 4 14
40–49 7 29
50–59 7 17
60–69 14 7
701 89
Median age 59 48
Country of birth
UK 42 65
Non-UK 2 15
Marital status
Married/living as married 28 53
Divorced/separated/widowed 11 14
Single 5 11
Missing data 0 2
Children
Yes 32 57
No 10 20
Missing data 2 3
Timing of interview
Prediagnosis 26 37
Postdiagnosis 18 43
Mode of referral
Urgent to gynae 11 22*
Directly to ultrasound scan 11 58**
Urgent to other specialties 9
Routine to gynae 4
Routine to ultrasound scan 1
Accident & Emergency 5
Other 3
Outcome Borderline: 13 Benign ovarian
cyst(s): 32
Stage I: 5 Benign ovarian
cyst(s) and
ﬁbroids: 7
Stage II: 1
Stage III: 12 Fibroids: 15
Stage IV: 1 Nothing abnormal
detected 21
Not known:*** 8 Others: 5
Peritoneal cancer: 2
Genital organ
cancer not
otherwise
speciﬁed 2
*19 of 22 urgent referrals to gynae clinics underwent diagnostic
surgery.
**25 of 58 referred to USS underwent surgery.
***All women with unstaged carcinoma were receiving
chemotherapy or palliative care due to suspected advanced-stage
disease (stage III or IV). The stage is not known as the tumour
had not been excised and staged prior to treatment commencing.
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During the transformation process, symptoms were marked
as present or absent on the basis of women’s descriptions of
their experiences. Abdominal distension and bloating were
coded as one variable with three categories: neither bloating
nor distension, bloating alone and abdominal distension, with
or without bloating. The referent category was neither bloat-
ing nor distension.
Univariate results
Nine variables were signiﬁcant at the signiﬁcance level of P <
0.05 and had greater than ﬁve expected number of events. As
mentioned earlier, the cancer group were signiﬁcantly older
than the noncancer group, which reﬂects the pattern of inci-
dence of ovarian cancer and the imbalance is due to the pro-
spective nature of the data collection. Of the other eight
variables, seven occurred more frequently in the cancer group
than in the noncancer group (abdominal distension, early
satiety, indigestion, vomiting, loss of appetite, feeling hotter
than usual and progression or worsening of symptoms).
Intramenstrual bleeding was more prevalent among the non-
cancer group.
Examination of the variable of abdominal distension and
bloating revealed that 38 of the women diagnosed with cancer
experienced distension (sensitivity of 86.4%, 95% CI 72.6–
94.8%) compared with 38 (47.5%) of those without cancer
(specificity of 52.5%, 95% CI 41.0–63.8%). In contrast, only
two women with cancer experienced abdominal bloating
(without distension) (sensitivity of 4.5%, 95% CI 0.6–
15.5%) compared with 22 (27.5%) women without cancer
(specificity of 72.5%, 95% CI 61.4–81.9%). This pattern has
not previously been reported.
Multivariate results
The nine variables above (including age) and those of ab-
normal vaginal bleeding (as likely to be affected by the age
difference between the two groups) were entered into the
main effects model, resulting in 15 variables being included.
The six variables associated with abnormal vaginal bleeding
were menorrhagia, missed or irregular periods, PMB, post-
coital bleeding, vaginal discharge and worsening of other
symptoms while experiencing bleeding.
Multivariate analysis revealed abdominal distension, PMB,
loss of appetite, early satiety and progressive symptoms as in-
dependent variables associated with ovarian cancer (Table 2).
Bloating was not associated with ovarian malignancy.
A premature feeling of fullness while eating (early satiety)
was also strongly associated with the presence of ovarian
cancer and, like persistent distension, presumably reﬂects
the presence of an abdominal or pelvic mass. These are both
uncommon symptoms in primary care. Although the esti-
mated likelihood ratios are modest (persistent distension
1.4; early satiety 4.7), many of the women with these symp-
toms who did not have cancer had a nonmalignant mass such
as an ovarian cyst or ﬁbroids (26 of 38 with distension and 7
of 7 with early satiety).
The discriminatory power of the model was 81.5% (66%
of ovarian cancer cases were correctly classiﬁed and 90% of
noncases).
Discussion
Ovarian cancer is not a silent killer. All women with ovarian
cancer experienced symptoms prior to diagnosis. While this is
not surprising, as the cohort of women in the study had con-
sulted their GPs and been referred to hospital, our ﬁndings do
suggest that the symptom experiences of women ultimately
diagnosed with ovarian cancer are different from those not
diagnosed with ovarian malignancy. This has important
implications as the majority of women currently diagnosed
with ovarian cancer are not initially referred to gynaecological
cancer clinics.5 Moreover, the symptoms appear to have been
Table 2. Multivariable logistic regression analysis of prediagnosis symptoms associated with the diagnosis of ovarian cancer
Variable* Number (%) with this variable present Odds ratios
Cases (n 5 44) Noncases (n 5 80) Crude Adjusted (95% CI)
Bloating and distension
None 4 (9.1) 22 (27.5) 1.0 1.0
Bloating alone 2 (4.5) 22 (27.5) 0.6 0.4 (0.0–4.1)
Abdominal distension (bloating) 38 (86.4) 38 (47.5) 5.5 5.2 (1.3–20.5)
Early satiety 18 (40.9) 7 (8.8) 7.2 5.0 (1.6–15.7)
Loss of appetite 17 (38.6) 13 (16.3) 3.2 3.2 (1.1–9.2)
PMB 6 (13.6) 2 (2.5) 6.2 9.2 (1.1–76.1)
Progression/worsening of symptoms 26 (59.1) 29 (36.3) 2.5 3.6 (1.3–9.8)
*For all risk measures, ‘none’ is the reference category. The analysis is adjusted for age.
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Similarly, a recent consensus statement,25 which was accom-
panied by an editorial in the Lancet,26 concluded that women
do have symptoms, primarily gastrointestinal and urinary, for
several months prior to diagnosis.
Qualitativeandquantitativeanalysesdemonstratedthatper-
sistent abdominal distension was associated with the diagnosis
of ovarian cancer (38 of 44 women with cancer). In contrast,
bloating (ﬂuctuating change) was not shown to be associated
with the disease (2 of 44 with cancer). This is in opposition to
previous research, which has reported that abdominal bloating
is one of the main features of ovarian cancer.12,14,16 The dis-
crepancy may be attributed to the novel approach to data
collection used in this study—the use of qualitative and quan-
titative methods enabled the identification of a much broader
set of potential symptoms and allowed a deeper understanding
of women’s symptom experiences.
The terminology used by women to name their symptoms
did not always accurately describe the symptoms they expe-
rienced. This was most evident in the case of persistent
abdominal distension and ﬂuctuating distension/discomfort,
both of which women frequently called bloating. Such duality
of labelling by the women was an unexpected ﬁnding. It is
likely that previous research has suffered from over-reporting
and misinterpretation of the term bloating.
Women frequently present in primary care with bloating.
However, persistent abdominal distension is signiﬁcantly less
common. In order to distinguish between women experienc-
ing persistent abdominal distension and those with ﬂuctuat-
ing change, GPs could further question women consulting
with symptoms of bloating. Women who might beneﬁt from
further investigations and referral to gynaecological cancer
clinics may therefore be identiﬁed.
Goff et al. have recently developed a symptom index for
ovarian cancer.10 The index was subsequently tested in a sep-
arate group of women and controls. Although this technique
of development and validation is the preferred method of
developing a set of discriminatory features, the data were
collected using a symptom checklist. The use of checklists
can be problematic because the data collected rely on the
checklist being comprehensive and women’s interpretations
of the listed symptoms are unknown. Previous research
(including the Goff study) has tended to group together
abdominal distension and bloating into one broad checklist
category, thereby limiting opportunities to investigate the
subtleties of the distinction we have found. Also, it is possible
that women experiencing persistent abdominal distension
completing a checklist including a symptom such as bloating
would tick that checkbox in addition to the one correspond-
ing to an increase in abdominal size. The occurrence of bloat-
ing would therefore be overestimated.
Other previous symptom research has used medical re-
cords to collect data, but this is likely to under-represent
the experiences of women, as only those symptoms that are
deemed salient by the clinician tend to be documented. This
was illustrated in a systematic review and meta-analysis, car-
ried out as part of this research: medical record data indicated
that 22.6% of women were asymptomatic, whereas only 7.2%
of women reporting data directly had no symptoms.7
A limitation of our mixed-method approach was that it was
necessary to restrict the sample size in order to effectively
manage the qualitative data collection and analysis. Although
the data allowed the development of a discriminatory model
to estimate the magnitude of association between each symp-
tom and a cancer diagnosis, the conﬁdence intervals were
wide and the analysis should be considered as hypothesis
generating. The model was not tested in an independent data
set, and therefore, further validation is required. However,
given the limitations of previous research (largely retrospec-
tive, use of medical notes, use of restrictive symptom check-
lists for direct data collection), the present study has made
important progress in identifying symptoms that may be in-
dicative of ovarian cancer. Although the predictive values need
validation, the requirement to listen to symptom narratives
with care and explore what women are describing in using
the term bloating is clear.
Although every effort was made to interview participants
prior to diagnosis, this only occurred in just over half of the
participants. However, there did not seem to be any qualita-
tive difference in the symptom proﬁles of women interviewed
in the differing time frames. Furthermore, a subgroup analysis
examining the frequencies of symptoms within the cancer
group was conducted to investigate if there were any differ-
ences between the interviews conducted before diagnosis and
those completed after diagnosis. If a bias exists, symptoms
should be reported more frequently in the interviews con-
ducted after diagnosis as a greater emphasis may be placed
on these symptoms once a participant knows that they have
got a signiﬁcant disease. However, the opposite pattern was
observed in the subgroup analysis, and therefore, it is reason-
able to conclude thata systematic bias was not introduced due
to the timing of the interview.
Nonresponse bias is a possibility, and this would need to be
carefully considered in a future validation study. However, no
exclusion criteria were used, and therefore, women with poor
performance status were included, so we believe that infor-
mation representing a broad spectrum of the disease proﬁle
was obtained.
Conclusions
In the absence of more deﬁnitive diagnostic tools, early detec-
tion of ovarian cancer will continue to challenge the skill of
astute clinicians as well as their accumulated scientiﬁc acu-
men.27 This study has shown that there may be an opportu-
nity to effect a change in primary care if GPs were to probe
Bankhead et al.
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and ﬂuctuating distension as this difference has the potential
to discriminate between women with and without ovarian
cancer, respectively. This simple action may lead to more
rapid and appropriate referrals for women with suspected
ovarian malignancy.
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